Skip to main content

Table 4 HIV treatment and other determinants of abnormal lipid profile in HIV-infected individuals in Yaounde, Cameroon

From: First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study

Outcome variables

Explanatory variables

Adjusted OR

(95% CI)

P

TC ≥ 200 (mg/dl)

Antiretroviral therapy

1.82 (1.06-3.12)

0.02

 

Sex (Women vs. Men)

0.83 (0.48-1.43)

0.49

 

Age > 40 years

1.27 (0.74-2.17)

0.39

 

BMI > 25 kg/m2

1.05 (0.59-1.86)

0.87

 

Active tuberculosis

0.49 (0.28-0.86)

0.01

 

CD4 count ≤ 200/mm3

2.56 (0.34-20.00)

0.36

LDL-c ≥ 130 (md/dl)

Antiretroviral therapy

2.99 (1.74-5.15)

< 0.0001

 

Sex (Women vs. Men)

1.06 (0.61-1.82)

0.84

 

Age > 40 years

1.13 (0.66-1.94)

0.65

 

BMI > 25 kg/m2

1.87 (1.07-3.27)

0.02

 

Active tuberculosis

0.54 (0.31-0.95)

0.03

 

CD4 count ≤ 200/mm3

1.92 (0.24-15.74)

0.54

TC/HDL-c ratio ≥ 5

Antiretroviral therapy

1.73 (1.04-2.89)

0.03

 

Sex (Women vs. Men)

1.88 (1.11-3.20)

0.02

 

Age > 40 years

1.49 (0.89-2.50)

0.20

 

BMI > 25 kg/m2

0.68 (0.40-1.17)

0.16

 

Active tuberculosis

1.12 (0.67-1.89)

0.68

 

CD4 count ≤ 200/mm3

1.78 (0.22-14.43)

0.59

  1. BMI, body mass index; OR, odds ratio; CI, confidence interval; LDL-c, LDL cholesterol;
  2. TC, total cholesterol; HDL-c, HDL cholesterol